122893-33-8

Upstream product

• 122893-31-6 4-(2-Pyrrolidin-1-yl-ethoxy)-benzaldehyde oxime; hydrochloride 
• 215656-53-4 4-[2-(1-pyrrolidinyl)ethoxy]benzamide 

Downstream Products

• 128540-41-0 3,4,5-Trimethoxy-N-[4-(2-pyrrolidin-1-yl-ethoxy)-benzyl]-benzamide 
• 215656-54-5 N-[4-[2-(1-pyrrolidinyl)ethoxy]benzyl]-2-nitroaniline 
• 122892-33-5 2,4-Dimethoxy-N-[4-[2-(1-pyrrolidinyl)ethoxy]benzyl]benzamide 
• 122892-32-4 3,4-Methylenedioxy-N-[4-[2-(1-pyrrolidinyl) ethoxy]benzyl] benzamide 
• 25054-53-9 3,4-(methylenedioxy)benzoyl chloride 

Relevant academic research and scientific papers

Antithrombotic agents

The invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts, as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.

Synthesis, gastrointestinal prokinetic activity and structure-activity relationships of novel N-[[2-(dialkylamino)ethoxy]benzyl]benzamide derivatives

Novel N-[[2-(dialkylamino)ethoxy]benzyl]benzamide derivatives (II-1-51), derived from the structural modification of metoclopramide (1), were synthesized and examined for their pharmacological activities. Among them, N-[4-[2-(dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide (II-34) which exhibited well balanced gastrointestinal prokinetic and antiemetic activities was selected as a new type of gastrointestinal prokinetic agent.